ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
4D Molecular Therapeutics Inc

4D Molecular Therapeutics Inc (FDMT)

23.96
-0.94
(-3.78%)
Closed May 29 4:00PM
23.96
0.00
(0.00%)
After Hours: 7:30PM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
23.96
Bid
22.31
Ask
25.75
Volume
379,944
23.95 Day's Range 24.61
9.44 52 Week Range 36.25
Market Cap
Previous Close
24.90
Open
24.42
Last Trade
40
@
23.95
Last Trade Time
Financial Volume
$ 9,235,802
VWAP
24.3083
Average Volume (3m)
568,910
Shares Outstanding
49,778,127
Dividend Yield
-
PE Ratio
-11.82
Earnings Per Share (EPS)
-2.03
Revenue
20.72M
Net Profit
-100.84M

About 4D Molecular Therapeutics Inc

4D Molecular Therapeutics Inc a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built portfolio of gene therapy product candidates focused in three therapeutic areas: ophthalmology (intravitreal vector), cardiology (... 4D Molecular Therapeutics Inc a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built portfolio of gene therapy product candidates focused in three therapeutic areas: ophthalmology (intravitreal vector), cardiology (intravenous vector) and pulmonology (aerosol vector). It has three product candidates in clinical trials: 4D-125 for the treatment of X-linked retinitis pigmentosa in a Phase 1/2 clinical trial, 4D-110 for the treatment of choroideremia in a Phase 1 clinical trial, and 4D-310 for the treatment of Fabry disease in a Phase 1/2 clinical trial. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration, and 4D-710 for the treatment of cystic fibrosis lung disease. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
Wilmington, Delaware, USA
Founded
1970
4D Molecular Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker FDMT. The last closing price for 4D Molecular Therapeutics was $24.90. Over the last year, 4D Molecular Therapeutics shares have traded in a share price range of $ 9.44 to $ 36.25.

4D Molecular Therapeutics currently has 49,778,127 shares outstanding. The market capitalization of 4D Molecular Therapeutics is $1.19 billion. 4D Molecular Therapeutics has a price to earnings ratio (PE ratio) of -11.82.

FDMT Latest News

4DMT Reports First Quarter 2024 Financial Results and Operational Highlights

Announced positive interim data from PRISM Phase 2 Dose Expansion cohort evaluating 4D-150 in wet AMD patients with severe disease activity and high treatment burden enabling advancement into...

4DMT to Participate in Upcoming Investor Conference

EMERYVILLE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the...

4DMT Announces Presentations at ARVO 2024 Annual Meeting

Preclinical data for 4D-175 for geographic atrophy to be presented in an oral presentation4D-150 PRISM randomized Phase 2 Dose Expansion Cohort (N=51) 24-week encore results to be presented in a...

4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis

Conducted initial pivotal study interactions with the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA); Company has clear registration path for 4D-710 for treatment of...

4DMT to Participate in Upcoming Investor Conferences

EMERYVILLE, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-1.22-4.8451151707725.1826.5323.9542075925.44834409CS
4-0.04-0.1666666666672427.8423.9543175125.75603404CS
12-3.2-11.782032400627.1636.2522.7556891028.19685779CS
2611.693.851132686112.3636.2512.1982001527.02675005CS
526.2435.214446952617.7236.259.4459294723.5271526CS
156-3.04-11.25925925932736.255.3240967320.39307452CS
260-16.04-40.14055.115.3237628521.57044693CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
LUCYInnovative Eyewear Inc
$ 0.9393
(129.10%)
576.2M
BNAIBrand Engagement Network Inc
$ 2.6062
(105.21%)
108.22M
ONCOOnconetix Inc
$ 0.2949
(79.93%)
137.82M
ASTSAST SpaceMobile Inc
$ 9.0199
(69.23%)
109.9M
KTRAKintara Therapeutics Inc
$ 0.272
(44.76%)
81.59M
FFIEFaraday Future Intelligent Electric Inc
$ 0.4379
(-62.57%)
417.92M
AWINAERWINS Technologies Inc
$ 5.555
(-39.22%)
2.01M
HLTHCue Health Inc
$ 0.0553
(-38.96%)
72.11M
GWAVGreenwave Technology Solutions Inc
$ 0.0494
(-37.15%)
676.15M
PLTNUPlutoniam Acquisition Corporation
$ 5.83
(-34.57%)
965
GWAVGreenwave Technology Solutions Inc
$ 0.0494
(-37.15%)
676.15M
LUCYInnovative Eyewear Inc
$ 0.9393
(129.10%)
576.2M
FFIEFaraday Future Intelligent Electric Inc
$ 0.4379
(-62.57%)
417.92M
RSLSReShape Lifesciences Inc
$ 0.2847
(37.01%)
212.55M
AALAmerican Airlines Group Inc
$ 11.62
(-13.54%)
159.16M

Your Recent History

Delayed Upgrade Clock